Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension

Journal of the American Society of Hypertension

Volumn 5, Issue 3, 2011, Pages 166-176

  Shah, Sukrut ^a   Hermanowski Vosatka, Anne ^a   Gibson, Kendra ^a   Ruck, Rae Ann ^a   Jia, Gang ^a   Zhang, John ^a   Hwang, Peggy M T ^a   Ryan, Nicholas W ^a   Langdon, Ronald B ^a   Feig, Peter U ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ambulatory blood pressure monitoring; dyslipidemia; low density lipoprotein cholesterol; Metabolic syndrome

Indexed keywords

AMITRIPTYLINE; ANTIHYPERTENSIVE AGENT; DUTASTERIDE; ESTROGEN; FINASTERIDE; FLUOXETINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MK 0736; MK 0916; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SITTING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79955639922     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2011.01.009     Document Type: Article

References (18)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23. (Pubitemid 40138015)
2. Feig PU, Roy S, Cody RJ. Antihypertensive drug development: current challenges and future opportunities. J Am Soc Hypertens 2010;4:163-73.
3. Galzerano D, Capogrosso C, Di Michele S, Bobbio E, Paparello P, Gaudio C. Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection. Vasc Health Risk Manag 2010;6:479-94.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285: 2486-97.
5. Thieringer R, Hermanowski-Vosatka A. Inhibition of 11β-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role? Expert Rev Cardiovasc Ther 2005;3:911-24.
6. Wamil M, Seckl JR. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007;12:504-20. (Pubitemid 47031664)
7. Cooper MS, Stewart PM. 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009;94: 4645-54.
8. Morton NM. Obesity and corticosteroids: 11β-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010;316: 154-64.
9. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, et al. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-66. (Pubitemid 39366049)
10. Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer M, Donahue S, et al. Effects of an 11β-hydroxysteroid dehydrogenase type 1 (HSD1) inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 2011 [Epub ahead of print].
11. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. J Hypertens 1991;9:573-4.
12. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322:531-6. (Pubitemid 32230920)
13. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
14. Allen BS, Smith JG Jr. Various parameters for grading acne vulgaris. Arch Dermatol 1982;118:23-5. (Pubitemid 12207199)
15. Sweetman SC. Corticosteroids. In: Sweetman SC, editor. Martindale-The complete drug reference. 34th ed. London: Pharmaceutical Press; 2005. p. 1068-71.
16. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, et al. The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010;33:1516-22.
17. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a metaanalysis. Am J Clin Nutr 1992;56:320-8.
18. Harno E, White A. Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis? Trends Endocrinol Metab 2010;21:619-27.